Trial Profile
Phase II, Open-Label Study of Erlotinib (Tarceva) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MuTAR
- Sponsors Roche
- 31 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Dec 2018
- 15 Mar 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Dec 2017.